Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.

e13079Background: Elevated ALP and LDH levels have been associated with worse prognosis in several malignancies; however, their role in MBC remains unclear. We aim to explore the prognostic impact of ALP and LDH levels at baseline and after 12 weeks of first line therapy in MBC patients (pts). Methods: This retrospective study analyzed 396 consecutive pts with a diagnosis of MBC, treated between 2007 and 2017 at the Oncology Department of Udine (Italy). The prognostic impact of elevated baseline ALP ( > 104 U/L) and LDH ( > 480 U/L), and their changes after 12 weeks of first line treatment were investigated through Cox regression. Results: After a median follow-up of 52.8 months, median overall survival (OS) was 30.9 months and median progression free survival (PFS) was 9.2 months. Pts with baseline elevated ALP or LDH were 33.8% (126/373) and 31.5% (70/222), respectively. The 16.9% (37/219) of pts had both elevated ALP and LDH. By univariate analysis, pts with baseline elevated levels of ALP (HR 1.82, 95...